Those receiving sofosbuvir/daclatasvir-based treatment was associated with numerically shorter length of hospital stay than control group, but the difference did not reach statistical significance [ 68 , 70 ].
← all excerpts
A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives.
1
—
—